Biomarkers like IL-6, IL-8, IL-1β, and IL-11 offer opportunities for early detection, patient stratification, and personalized treatment approaches, enhancing the clinical management of metastatic disease. This evidence concerns the gene IL11 and metastatic neoplasm.